Market Overview

OXiGENE Says Phase 2 Data on ZYBRESTAT May Produce Transient Cut

Share:
Related OXGN
H.C. Wainwright & Co. Retains Positive Outlook On OXiGENE
Stocks Hitting 52-Week Lows

OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), a degenerative eye disease.

Posted-In: News FDA

 

Related Articles (OXGN)

Around the Web, We're Loving...